Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118:3272–87.

CAS  Google Scholar 

Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail. 2020;22:1551–67.

PubMed  Google Scholar 

Kristensen SL, Jhund PS, Lee MMY, Køber L, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, McMurray JJV. CHARM investigators and committees. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther. 2017;31:545–9.

PubMed  PubMed Central  Google Scholar 

Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res. 2018;15:494–503.

PubMed  Google Scholar 

Tribouilloy C, Rusinaru D, Mahjoub H, Tartière J-M, Kesri-Tartière L, Godard S, Peltier M. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart Br Card Soc. 2008;94:1450–5.

CAS  Google Scholar 

Brannick B, Dagogo-Jack S. Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. Endocrinol Metab Clin North Am. 2018;47:33–50.

PubMed  PubMed Central  Google Scholar 

Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310–7.

PubMed  Google Scholar 

Sandesara PB, O’Neal WT, Kelli HM, Samman-Tahhan A, Hammadah M, Quyyumi AA, Sperling LS. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care. 2018;41:150–5.

CAS  PubMed  Google Scholar 

Khan MS, Shahid I, Anker SD, Fonarow GC, Fudim M, Hall ME, Hernandez A, Morris AA, Shafi T, Weir MR, Zannad F, Bakris GL, Butler J. Albuminuria and heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2023;81:270–82.

CAS  PubMed  Google Scholar 

Martens RJH, Houben AJHM, Kooman JP, Berendschot TTJM, Dagnelie PC, van der Kallen CJH, Kroon AA, Leunissen KML, van der Sande FM, Schaper NC, Schouten JSAG, Schram MT, Sep SJS, Sörensen BM, Henry RMA, Stehouwer CDA. Microvascular endothelial dysfunction is associated with albuminuria: the Maastricht study. J Hypertens. 2018;36:1178–87.

CAS  PubMed  Google Scholar 

Weerts J, Mourmans SG, Barandiarán Aizpurua A, Schroen BL, Knackstedt C, Eringa E, Houben AJ, van Empel VP. The role of systemic microvascular dysfunction in heart failure with preserved ejection fraction. Biomolecules. 2022;12:278.

CAS  PubMed  PubMed Central  Google Scholar 

Volpe M, Gallo G. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. Cardiovasc Res. 2021;117:1992–4.

CAS  PubMed  Google Scholar 

Bell DSH, Goncalves E. Heart failure in the patient with diabetes: epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. Diabetes Obes Metab. 2019;21:1277–90.

PubMed  Google Scholar 

Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet Lond Engl. 2022;400:757–67.

CAS  Google Scholar 

Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R. FLOW trial committees and investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109–21.

CAS  PubMed  Google Scholar 

Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, Banker A, Husami Z, Labib S, Venesy D, Fonarow G, Kosiborod M, Al-Kindi S, Bhatt DL, Dani S, Nohria A, Butler J, Ganatra S. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC Heart Fail. 2024;12:1814–26.

CAS  PubMed  Google Scholar 

Barandiaran Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca H-P, Henkens MT, Weerts J, Spanjers MH, Knackstedt C, van Empel VP. Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC Heart Fail. 2021;8:1304–13.

PubMed  PubMed Central  Google Scholar 

Henkens MTHM, Weerts J, Verdonschot JAJ, Raafs AG, Stroeks S, Sikking MA, Amin H, Mourmans SGJ, Geraeds CBG, Sanders-van Wijk S, Barandiarán Aizpurua A, Uszko-Lencer NHMK, Krapels IPC, Wolffs PFG, Brunner HG, van Leeuwen REW, Verhesen W, Schalla SM, van Stipdonk AWM, Knackstedt C, Li X, Abdul Hamid MA, van Paassen P, Hazebroek MR, Vernooy K, Brunner-La Rocca H-P, van Empel VPM, Heymans SRB. Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht cardiomyopathy registry. ESC Heart Fail. 2022;9:1463–70.

PubMed  PubMed Central  Google Scholar 

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Meer P van der, ESC Scientific Document Group. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC)Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;2016(37):2129–200.

Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;2021(42):3599–726.

Google Scholar 

Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in heart failure with preserved ejection fraction study (I-PRESERVE). Circ Heart Fail. 2011;4:27–35.

CAS  PubMed  Google Scholar 

Weerts J, Barandiarán Aizpurua A, Henkens MT, Lyon A, van Mourik MJ, van Gemert MR, Raafs A, Sanders-van Wijk S, Bayés-Genís A, Heymans SR. The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. Eur Heart J-Cardiovasc Imaging. 2022;23:74–84.

Google Scholar 

Harrell FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Cham: Springer International Publishing; 2015.

Google Scholar 

Zheng R, Qian S, Shi Y, Lou C, Xu H, Pan J. Association between triglyceride-glucose index and in-hospital mortality in critically ill patients with sepsis: analysis of the MIMIC-IV database. Cardiovasc Diabetol. 2023;22:307.

CAS  PubMed  PubMed Central  Google Scholar 

Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O’Meara E, Desai AS, Lewis EF, Pitt B, Sweitzer NK, Fang JC, Pfeffer MA, Solomon SD. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11: e005288.

PubMed  PubMed Central  Google Scholar 

Katz DH, Burns JA, Aguilar FG, Beussink L, Shah SJ. Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail. 2014;2:586–96.

PubMed  PubMed Central  Google Scholar 

Mgbemena O, Zhang Y, Velarde G. Role of diabetes mellitus in heart failure with preserved ejection fraction: a review article. Cureus. 2021;13: e19398.

PubMed  PubMed Central  Google Scholar 

Phang RJ, Ritchie RH, Hausenloy DJ, Lees JG, Lim SY. Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy. Cardiovasc Res. 2023;119:668–90.

CAS  PubMed  Google Scholar 

McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, Yancy CW, Green JB, Altman N, Hernandez AF. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:602–11.

PubMed  Google Scholar 

Son TK, Toan NH, Thang N, Le Trong TH, Tien HA, Thuy NH, Van Minh H, Valensi P. Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension. Cardiovasc Diabetol. 2022;21:75.

CAS  PubMed  PubMed Central  Google Scholar 

Jackson AM, Rørth R, Liu J, Kristensen SL, Anand IS, Claggett BL, Cleland JGF, Chopra VK, Desai AS, Ge J, Gong J, Lam CSP, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rizkala AR, Rouleau JL, Seferović PM, Tromp J, Van Veldhuisen DJ, Yilmaz MB, Zannad F, Zile MR, Køber L, Petrie MC, Jhund PS, Solomon SD, McMurray JJV. PARAGON-HF committees and investigators. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022;24:497–509.

CAS  PubMed  Google Scholar 

Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. HOPE study investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–6.

CAS  PubMed  Google Scholar 

Yamanouchi M, Sawa N, Toyama T, Shimizu M, Oshima M, Yoshimura Y, Sugimoto H, Kurihara S, Oba Y, Ikuma D, Mizuno H, Sekine A, Suwabe T, Hoshino J, Ubara Y, Hara S, Furuichi K, Wada T. Trajectory of GFR decline and fluctuation in albuminuria leading to end-stage kidney disease in patients with biopsy-confirmed diabetic kidney disease. Kidney Int Rep. 2024;9:323–33.

PubMed  Google Scholar 

Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol CJASN. 2007;2:581–90.

PubMed  Google Scholar 

Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.

PubMed  Google Scholar 

de Jong PE, Hillege HL, Pinto-Sietsma SJ, de Zeeuw D. Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2003;18:10–3.